OCGN

Ocugen, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

A key executive is leavingSince May 14, 2026+2

Trials

OCGNOcugen
2Calm
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
Running, no new patientsPhase 1/260 patientsMain results: Feb 3, 2026
OCGNOcugen
2Calm
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Signing up patientsPhase 3237 patientsMain results: Jul 30, 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

May 14, 2026
“Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.”
Read the filing ↗

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

4 sales (0 not pre-planned) · 1 purchase

Musunuri ShankarChief Executive Officer · Oct 9, 2026Sold 468,727 sharesabout $445 thousand · pre-planned
Musunuri ShankarChief Executive Officer · Oct 9, 2026Sold 57,264 sharesabout $54 thousand · pre-planned
Musunuri ShankarChief Executive Officer · Sep 9, 2026Sold 468,727 sharesabout $525 thousand · pre-planned
Musunuri ShankarChief Executive Officer · Sep 9, 2026Sold 57,264 sharesabout $64 thousand · pre-planned
Johnson-Greene Treerita EssalimaChief Financial Officer · Jun 15, 2026Bought 21,000 sharesabout $26 thousand ·

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.